Common Contracts

AMENDED AND RESTATED RESEARCH AND COLLABORATION AGREEMENT by and among Eli Lilly and Company and ProQR Therapeutics N.V. and ProQR Therapeutics VIII B.V. AMENDED AND RESTATED RESEARCH AND COLLABORATION AGREEMENT

Research and Collaboration Agreement • December 23rd, 2022 • ProQR Therapeutics N.V. • Pharmaceutical preparations • New York

• Contract Type
  Research and Collaboration Agreement
• Filed
  December 23rd, 2022
• Company
  ProQR Therapeutics N.V.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

This Amended and Restated Research and Collaboration Agreement (“Agreement”) entered into as of December 21st, 2022 (the “A&R Effective Date”), by and among ProQR Therapeutics N.V., a company organized and existing under the laws of the Netherlands, having its principal place of business at Zernikedreef 9, 2333 CK Leiden, The Netherlands, and ProQR Therapeutics VIII B.V., a company organized and existing under the laws of the Netherlands, having its principal place of business at Zernikedreef 9, 2333 CK Leiden, the Netherlands, (such entities, collectively, “ProQR”), and Eli Lilly and Company, a corporation organized and existing under the laws of Indiana, with its principal business office located at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A. (“Lilly”), amends, restates and supersedes in its entirety (except as expressly set forth herein), that certain Research and Collaboration Agreement, entered into as of September 3rd, 2021 (the “Effective Date”), by and among the

RESEARCH AND COLLABORATION AGREEMENT by and among Eli Lilly and Company and ProQR Therapeutics N.V. and ProQR Therapeutics VIII B.V.

Research and Collaboration Agreement • September 8th, 2021 • ProQR Therapeutics N.V. • Pharmaceutical preparations • New York

• Contract Type
  Research and Collaboration Agreement
• Filed
  September 8th, 2021
• Company
  ProQR Therapeutics N.V.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

This Research and Collaboration Agreement (“Agreement”) is entered into as of September 3rd, 2021 (the “Effective Date”), by and among ProQR Therapeutics N.V., a company organized and existing under the laws of the Netherlands, having its principal place of business at Zernikedreef 9, 2333 CK Leiden, The Netherlands, and ProQR Therapeutics VIII B.V., a company organized and existing under the laws of the Netherlands, having its principal place of business at Zernikedreef 9, 2333 CK Leiden, the Netherlands, (such entities, collectively, “ProQR”), and Eli Lilly and Company, a corporation organized and existing under the laws of Indiana, with its principal business office located at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A. (“Lilly”). Lilly and ProQR are each hereafter referred to individually as a “Party” and together as the “Parties.”